Aston, Valerie

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021

Self, W. H., Tenforde, M. W., Rhoads, J. P., Gaglani, M., Ginde, A. A., Douin, D. J., Olson, S. M., Talbot, H. K., Casey, J. D., Mohr, N. M., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 406

Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021

Tenforde, M. W., Self, W. H., Naioti, E. A., Ginde, A. A., Douin, D. J., Olson, S. M., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 204

Effectiveness of Monovalent mRNA Vaccines Against COVID-19–Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States — IVY Network, 18 States, December 26, 2021–August 31, 2022

Surie, D., Bonnell, L., Adams, K., Gaglani, M., Ginde, A. A., Douin, D. J., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A., et al. (2022) · MMWR. Morbidity and Mortality Weekly Report

SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studies

Cited by 59